Bisoprolol Fumarate And Hydrochlorothiazide
Generic Name: bisoprolol fumarate and hydrochlorothiazide
Brand Names:
Bisoprolol Fumarate And Hydrochlorothiazide
Bisoprolol fumarate and hydrochlorothiazide tablets combine two antihypertensive agents in a once-daily dosage for the treatment of hypertension.
Overview
Bisoprolol fumarate and hydrochlorothiazide tablets combine two antihypertensive agents in a once-daily dosage for the treatment of hypertension.
Uses
Indicated in the management of hypertension.
Dosage
Therapy begins with one 2.5/6.25 mg tablet once daily, with titration every 14 days up to maximum dose of 20/12.5 mg once daily as needed.
Side Effects
Common side effects include dizziness (5.1%), fatigue (4.6%), diarrhea (4.3%), and headache (4.5%) in clinical trials.
Interactions
May potentiate other antihypertensive agents. Should not combine with other beta-blockers. Interacts with lithium and NSAIDs.
Warnings
Contraindicated in patients in cardiogenic shock, overt cardiac failure, second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity. Includes cardiac failure risks, abrupt cessation concerns, bronchospastic disease cautions, and acute angle-closure glaucoma risks.
Frequently Asked Questions
What is Bisoprolol Fumarate And Hydrochlorothiazide used for?▼
Indicated in the management of hypertension.
What are the side effects of Bisoprolol Fumarate And Hydrochlorothiazide?▼
Common side effects include dizziness (5.1%), fatigue (4.6%), diarrhea (4.3%), and headache (4.5%) in clinical trials.
What are the important warnings for Bisoprolol Fumarate And Hydrochlorothiazide?▼
Contraindicated in patients in cardiogenic shock, overt cardiac failure, second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity. Includes cardiac failure risks, abrupt cessation concerns, bronchospastic disease cautions, and acute angle-closure glaucoma risks.
Related Medications
Dextrose Monohydrate
dextrose monohydrate
Treatment of insulin-induced hypoglycemia in adults and pediatric patients aged 2 years and older.
Lebrikizumab-lbkz
lebrikizumab-lbkz
Interleukin-13 Antagonist [EPC]
11 DESCRIPTION Lebrikizumab-lbkz, an interleukin-13 antagonist, is an immunoglobulin G4 (IgG4) monoclonal antibody that binds to interleukin (IL)-13 and inhibits IL-13 signaling. Lebrikizumab-lbkz is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Lebrikizumab-lbkz has an approximate molecular weight of 145 kDa.
Dimethyl Fumarate Kit
dimethyl fumarate kit
11 DESCRIPTION Dimethyl Fumarate Delayed-Release Capsules contain dimethyl fumarate which is also known by its chemical name, dimethyl (E) butenedioate, (C 6 H 8 O 4 ). It has the following structure: Dimethyl fumarate is a white to off-white powder that is sparingly soluble in methanol; insoluble in water with a molecular mass of 144.13.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.